Sydnexis Announces Positive CHMP Opinion in Europe for SYD-101 for Slowing the Progression of Pediatric Myopia

Santen is Sydnexis’ Licensing Partner to Commercialize SYD-101 within the EMEA Region upon issuance of a Marketing Authorization by the European Commission DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc. (www.sydnexis.com), a pre-commercial stage biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for […]